Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: Comparison between 2007 and 2009

Human Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 70-75

  Yoshio, Takashi ^a,j,k   Inada, Toshiya ^b   Uno, Junji ^c   Miwa, Takaichi ^d   Kitagawa, Kohei ^e   Miyahara, Yoshiki ^f   Umeda, Kenta ^g   Kato, Tsuyoshi ^h   Inagaki, Ataru ⁱ   Nabeshima, Toshitaka ^j,k  

^a TOHO UNIVERSITY   (Japan)

^b SEIWA HOSPITAL   (Japan)

^c Okehazama Hospital   (Japan)

^d Yuge Hospital   (Japan)

^e OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^f OSAKA GENERAL MEDICAL CENTER   (Japan)

^g Division of Pharmacy   (Japan)

^h Department of Pharmacy   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

^j MEIJO UNIVERSITY   (Japan)

^k Japanese Drug Organization of Appropriate Use and Research   (Japan)

more..

Author keywords

medication; polypharmacy; prescription survey; schizophrenia; second generation antipsychotics

Indexed keywords

ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BIPERIDEN; BLONANSERIN; CARBAMAZEPINE; CHLORPROMAZINE; DIAZEPAM; HYPNOTIC AGENT; LITHIUM CARBONATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; JAPAN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84856321088     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1272     Document Type: Article

References (25)

1. Bitter I, Chou CY, Ungvari GS, et al,. 2003. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 36: 143-149. (Pubitemid 37041334)
2. Chong MY, Tan CH, Fujii S, et al,. 2004. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatr Clin Neurosci 58: 61-67. (Pubitemid 38200373)
3. Dixon L, Weiden PJ, Frances AJ, Rapkin B,. 1989. Management of neuroleptic-induced movement disorders: effects of physician training. Am J Psychiatry 146 (1): 104-106. (Pubitemid 19033235)
4. Farde L, Wiesel FA, Halldin C, Sedvall C, Central G,. 1988. D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotics. Arch Gen Psychiatry 45: 71-76. (Pubitemid 18018572)
5. Gardos G,. Antipsychotic polypharmacy or monotherapy? 2005. Neuropsychopharmacol Hung 7: 72-77.
6. Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD,. 2010. Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry 44: 372-377.
7. Inagaki A, Inada T,. 2008. Dose equivalence of psychotropic drugs. Part 21: Dose equivalence of novel antipsychotics V: Blonanserin. Jpn J Clin Psychopharmacol 11: 887-890, in Japanese.
8. Inagaki A, Inada T,. 2010. Dose equivalence of psychotropic drugs. Part 22: Dose equivalence of depot antipsychotics III: Risperidone long-acting injection. Jpn J Clin Psychopharmacol 13: 1349-1353, in Japanese.
9. Kane JM, Correll CU,. 2010. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71: 1115-1124.
10. Lehman AF, Steinwachs DM, The coinvestigators of the PORT project. 1998. Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull 24: 1-10. (Pubitemid 28128486)
11. Lerner V, Chudakova B, Kravets S, et al,. 2000. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 23: 284-286. (Pubitemid 32014479)
12. Loga-Zec S, Loga S,. 2011. Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F/BH). Psychiatr Danub 23: 60-63.
13. Mace S, Taylor D,. 2005. A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance. Int J Psychiatry Clin Pract 9: 124-129. (Pubitemid 40874108)
14. Martine EW,. 1971. Hazards of medication: a manual on drug interactions, compatibilities, contraindications, and adverse effects. Lippincott: Philadelphia.
15. Megna JL, Kunwar AR, Mahlotra K, et al,. 2007. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 13: 129-137. (Pubitemid 46588318)
16. Ogino S, Miyamoto S, Tenjin T, et al,. 2011. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 78-83.
17. Pandurangi AK, Dalkilic A,. 2008. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pact 14: 345-367.
18. Sernyak MJ, Rosenheck RA,. 2008. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr Serv 59: 567-569.
19. Shinfuku N, Tan CH,. 2008. Pharmacotherapy for schizophrenic inpatients in East Asia-changes and challenges. Int Rev Psychiatry 20: 460-468.
20. Sim K, Su A, Fujii S, et al,. 2004. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58: 178-183. (Pubitemid 39043998)
21. Tandon R, Belmaker RH, Gattaz WF, et al,. 2008. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100: 20-38.
22. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E,. 2008. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31: 7-20.
23. Xiang YT, Wang CY, Si TM, et al,. 2011. Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry 44: 114-118.
24. Yip KC, Ungvari GS, Cheung HK, Ng FS, Lau ST,. 1997. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J (Engl) 110: 792-796. (Pubitemid 27443738)
25. Yoshio T, Uno J, Nakagawa M, et al,. 2010. Study of the prescriptions for psychopharmacology treatment in Japanese inpatients with schizophrenia in 2006. Jpn J Clin Psychopharmacol 13: 1535-1545, in Japanese.